Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01871948 · ClinicalTrials.gov registry record · NA

Effective Communication for Preventing and Responding to Oncology Adverse Events

A NA study of Cancer, sponsored by University of Massachusetts, Worcester.

Completed
Registry status
NA
Development phase
500
Enrollment target
2
Study locations

NCT01871948: Completed NA study of Cancer, sponsored by University of Massachusetts, Worcester.

NCT01871948 is a NA study of Cancer that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 500 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01871948, a NA study of Cancer, has completed, sponsored by University of Massachusetts, Worcester.

COMPLETED
Registry status
NA
Development phase
500 participants
Enrollment target
2
Study locations

Study Summary

Cancer patients often experience problems in their care, many of which are caused by communication breakdowns. Some communication breakdowns lead to adverse events and even harmful errors. Deficiencies in provider-patient communication can compound patients' distress, lower the quality of care, and disrupt patient-provider relationships. There is little research on patients' and providers' experiences of the communication breakdowns that precipitate adverse events and errors, or on effective responses to these events. Because of this, cancer providers are unsure how to communicate with patients in these difficult situations. The goal of the proposed study is to improve patient-centered communication around adverse events and errors in cancer care. Our specific aims are: 1) To describe patients' experiences with communication around adverse events and errors in cancer care, 2) To describe providers' experiences and practices with communication around adverse events and errors in cancer care, 3) To develop practical recommendations, provider training materials and patient educational materials for improving communication around adverse events and errors in cancer care, 4) To disseminate the recommendations and materials through three health plans, and 5) To conduct a preliminary evaluation of the perceived usefulness and impact of the materials. The investigators will first conduct interviews with breast and colorectal cancer patients who have experienced adverse events or errors at 3 Cancer Research Network (CRN) health plans (Atlanta, Georgia; Seattle, Washington and Worcester, Massachusetts). The interviews will focus on instances where patients believe that better communication might have prevented an adverse event or error, or mitigated the event's impact. Next the investigators will conduct focus groups to understand providers' attitudes and experiences with these communication dilemmas, and use simulations to describe providers' communication practices. Finally

Conditions Studied

Interventions

  • OTHER "We Want to Know" campaign, Patient survey at 2 time points

Study Locations (2)

Georgia

  • Kaiser Permanente Georgia - Atlanta

Washington

  • Group Health - Seattle

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2008-10
Est. Completion 2013-08
Phase NA

What the finished NCT01871948 record still lists

NCT01871948 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which "We Want to Know" campaign, Patient survey at 2 time points is the first listed.

NCT01871948 reports a single indexed study location in Georgia, Washington.

Frequently Asked Questions

What is clinical trial NCT01871948 about?

NCT01871948 is a clinical study titled "Effective Communication for Preventing and Responding to Oncology Adverse Events". Cancer patients often experience problems in their care, many of which are caused by communication breakdowns. Some communication breakdowns lead to adverse events and even harmful errors. Deficiencies in provider-patient communication can compound patients' distress, lower the quality of care, and ...

What is the current status of trial NCT01871948?

This trial is currently completed. It is a NA study. The enrollment target is 500 participants. The study started on 2008-10. Estimated completion is 2013-08.

What conditions does trial NCT01871948 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT01871948?

The interventions under investigation include: "We Want to Know" campaign, Patient survey at 2 time points (OTHER).

Who is sponsoring clinical trial NCT01871948?

This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01871948 being conducted?

This trial has 2 study locations across Georgia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01871948's enrollment target sits among peer trials

500 122nd of 615 higher than 484 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01871948, the US trial registry maintained by the National Library of Medicine. NCT01871948 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.